Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.
Its products are being sold in India and also expoted to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.
Competitive strengths
- Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
- Export products in Europe, Latin America, North America, Japan, and the rest of the world.
- Strong relationship with leading global generic companies.
- Proven track record of strong financial performance.
- High-quality product manufacturing with R&D infrastructure.
Company Promoters
- Glenmark Pharmaceuticals Limited
Company Financials:
| Particulars | For the year/period ended (₹ in million) | ||
|---|---|---|---|
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | |
| Total Assets | 19,970.75 | 17,256.04 | 14,753.95 |
| Total Revenue | 18,859.76 | 15,493.03 | 8,868.65 |
| Profit After Tax | 3,515.81 | 3,130.98 | 1,955.92 |
Objects of the Issue:
- To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
- To finance capital expenditure requirements.
- To meet general corporate purposes.
Glenmark Life Sciences IPO Date & Price Band
| IPO Open: | 27 July 2021 |
| IPO Close: | 29 July 2021 |
| IPO Size: | Approx ₹1514 Crores |
| Fresh Issue: | Approx ₹1060 Crores |
| Offer for Sale: | Approx ₹454 Crores, 63,00,000 Shares |
| Face Value: | ₹2 Per Equity Share |
| Price Band: | ₹695 to ₹720 Per Share |
| Listing on: | BSE & NSE |
| Retail Portion: | 35% |
| Equity: | – Shares |
Glenmark Life Sciences IPO Market Lot
The Glenmark Life Sciences IPO minimum market lot is 20 shares with ₹14,400 application amount. The retail investors can apply up-to 13 lots with 260 shares or ₹187,200 amount.
| Minimum Lot Size: | Minimum 20 Shares |
| Minimum Amount: | ₹14,400 |
| Maximum Lot Size: | Maximum 260 Shares |
| Maximum Amount: | ₹187,200 |
Glenmark Life Sciences IPO Date, Time Table, Allotment & Listing
The Glenmark Life Sciences IPO date is 27 July 2021 and the IPO close date is 29 July 2021. The allotment date is 03 August 2021 and the IPO may list on 06 August 2021.
| Basis of Allotment: | 27 July 2021 |
| Basis of Allotment: | 29 July 2021 |
| Basis of Allotment: | 03 August 2021 |
| Refunds: | 04 August 2021 |
| Credit to Demat Account: | 05 August 2021 |
| Listing Date: | 06 August 2021 |
Glenmark Life Sciences IPO Registrar
KFin Technologies Private Limited (Formerly known as
Karvy Fintech Private Limited)
Selenium Tower-B
Plot No-31 and 32, Financial District
Nanakramguda, Serilingampally
Hyderabad, Rangareddi 500032
Telangana, India
Tel: +91 40 6716 2222
E-mail: glenmark.ipo@kfintech.com
Investor Grievance E-mail: einward.ris@kfintech.com
Website: www.kfintech.com
Contact Person: M Murali Krishna
SEBI Registration No.: INR000000221
Note: Check Glenmark Life Sciences IPO allotment status on KFintech website allotment URL. Click Here
Glenmark Life Sciences IPO Lead Managers
- Kotak Mahindra Capital Company Limited
- BofA Securities India Limited
- Goldman Sachs (India) Securities Private Limited
- DAM Capital Advisors Limited
- BOB Capital Markets Limited
- SBI Capital Markets Limited
Company Address
Glenmark Life Sciences Limited
Registered Office:
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213, Maharashtra
Corporate Office:
Glenmark House, B. D. Sawant Marg,
Andheri (East), Mumbai 400099,
Maharashtra, India
Tel: +912189 234456/ +912189 234246
Website: www.glenmarklifesciences.com
Contact Person: Rudalf Corriea
(Company Secretary and Compliance Officer)
E-mail: complianceofficer@glenmarklifesciences.com
Corporate Identity Number: U74900PN2011PLC139963